Research
Energy balance
SGLT2 inhibitors improve cardiac energy efficiency in failing diabetic hearts by shifting fuel utilization from fatty acids to ketone bodies, which act as a 'super-fuel' that generates ATP more efficiently.
SGLT2 inhibitors change how your heart gets energy. Instead of struggling to burn fat, your heart efficiently burns ketones produced by the drug, which provides more energy with less stress, helping a failing heart function better.
GoodSupportsHIGH confidence
혈중 케톤체가 증가할 수 있는 조건이 되면, 케톤체를 우선적으로 활용하게 된다[24]. 심근으로 전달된 케톤체는 아세틸조효소A (acetyl-coenzyme, CoA)로 신속히 전환되어 크렙스회로(Krebs cycle)로 들어가 효율적으로 에너지(ATP)를 생성하게 되며... 케톤체는 포도당이나 유리 지방산을 대체하여 효율적으로 심근의 에너지원으로 사용되는, 소위 'super-fuel'의 역할을 담당하게 된다.
Why this rating
Supported by mouse studies and physiological hypotheses (EMPA-REG thrifty substrate hypothesis).
Source
The Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors
Jae‐Han Jeon · Journal of Korean Diabetes · 2019
DOI 10.4093/jkd.2019.20.2.81
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors provide cardioprotection through hemodynamic improvements, specifically by reducing preload and afterload via osmotic diuresis and natriuresis, which decreases ventricular wall tension and myocardial oxygen consumption.Good
- SGLT2 inhibitors reduce systemic inflammation and oxidative stress by decreasing body fat mass and improving insulin resistance, which lowers inflammatory markers like IL-6 and TNF-alpha.Good
- SGLT2 inhibitors protect kidney function by restoring tubuloglomerular feedback, which reduces glomerular hyperfiltration and intraglomerular pressure, thereby indirectly reducing cardiovascular disease risk.Good
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →